Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Representative image: A monitored sleep study and oral medication illustrate Incannex Healthcare’s DReAMzz Phase 2 screening program as the company refines IHL-42X dosing before a planned Phase 3 obstructive sleep apnea trial.
Pharma & Biotech

Incannex Healthcare begins DReAMzz screening to refine IHL-42X dosing before Phase 3 sleep apnea trial

Incannex Healthcare begins DReAMzz screening to select an IHL-42X dose before Phase 3. Read what the sleep apnea study must prove.

Read More
Representative image: Clinical researchers review cardiopulmonary data and oral therapy options as Inhibikase Therapeutics advances IKT-001 in a pivotal Phase 3 trial for pulmonary arterial hypertension following FDA Orphan Drug Designation.
Pharma & Biotech

Inhibikase Therapeutics gains FDA orphan status for IKT-001 as pivotal PAH trial advances

Inhibikase Therapeutics wins FDA orphan status for IKT-001 as its pivotal PAH trial tests whether a prodrug can improve imatinib tolerability.

Read More
Representative image: Laboratory researchers assess an oral blood disorder therapy as Nuvectis Pharma’s ciprocopan secures China approval for treatment-naive paroxysmal nocturnal hemoglobinuria.
Pharma & Biotech

Ciprocopan China approval gives PNH patients a new once-daily oral Factor B treatment option

Nuvectis Pharma’s ciprocopan wins China approval for PNH. Read how the once-daily Factor B drug could reshape the global treatment race.

Read More
Biotechnology leaders and oncology researchers discuss next-generation cancer therapies as the Society for Immunotherapy of Cancer prepares its European immuno-oncology drug development summit in Lausanne. Representative image.
Pharma & Biotech

Europe’s immuno-oncology pipeline has a translation problem. Can SITC’s Lausanne summit fix it?

SITC’s Lausanne summit will connect regulators, biotech and academia to sharpen Europe’s path from immuno-oncology science to clinical trials.

Read More
Verastem Oncology advances its VS-7375 development programme as the TARGET-D 202 Phase 2 trial begins evaluating the investigational KRAS G12D inhibitor in previously treated advanced non-small cell lung cancer. Representative image.
Pharma & Biotech

Verastem has entered the KRAS G12D lung cancer race, but can VS-7375 close the evidence gap?

Verastem begins TARGET-D 202, testing 900 mg VS-7375 in previously treated KRAS G12D NSCLC, including a brain metastases cohort.

Read More
Corcept Therapeutics’ second-quarter results will put early Lifyorli launch momentum, Korlym growth and the relacorilant FDA review under close scrutiny. Representative image.
Pharma & Biotech

Corcept Therapeutics sets July 29 Q2 call as Lifyorli launch and relacorilant review take centre stage

Corcept Therapeutics will report Q2 results on July 29, with Lifyorli launch sales, Korlym growth and relacorilant’s FDA review in focus.

Read More
Affinia Therapeutics’ AFTX-201 gene therapy is advancing through the UPBEAT trial after receiving FDA Orphan Drug designation for BAG3-associated dilated cardiomyopathy. Representative image.
Pharma & Biotech

Affinia Therapeutics advances AFTX-201 gene therapy for BAG3 dilated cardiomyopathy

Affinia Therapeutics gains FDA orphan status for AFTX-201 as the UPBEAT trial tests gene therapy for BAG3 dilated cardiomyopathy.

Read More
Zai Lab prepares to report second-quarter 2026 results as investors assess revenue recovery, new China product launches and progress across its oncology and neuroscience pipeline. Representative image.
Pharma & Biotech

Zai Lab’s August 6 earnings could reveal whether its 2026 commercial reset is starting to work

Zai Lab reports Q2 2026 results on August 6 as investors assess revenue pressure, COBENFY and TIVDAK launches, and zoci pipeline progress.

Read More
Clinical researchers review Phase 3 data for plozasiran after Arrowhead Pharmaceuticals reported substantial triglyceride reductions and fewer acute pancreatitis events in the SHASTA-3 and SHASTA-4 studies. Representative image.
Pharma & Biotech

SHASTA-3 and SHASTA-4 results support Arrowhead Pharmaceuticals’ planned plozasiran FDA filing

Arrowhead’s Phase 3 SHASTA data show deep triglyceride reductions and fewer pancreatitis events, supporting a planned 2026 U.S. filing.

Read More
Tikva Allocell’s $8 million Series A financing will support development of TAVST01, an engineered EBV-specific B7-H3 CAR-T therapy designed for potential use against solid tumors. Representative image.
Pharma & Biotech

Can Tikva Allocell’s $8m bet solve the persistence problem holding back off-the-shelf CAR-T?

Tikva Allocell raises $8 million to advance TAVST01 toward an IND, testing an EBV-specific CAR-T approach for B7-H3-positive solid tumors.

Read More